236 related articles for article (PubMed ID: 16940419)
1. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
Navas TA; Mohindru M; Estes M; Ma JY; Sokol L; Pahanish P; Parmar S; Haghnazari E; Zhou L; Collins R; Kerr I; Nguyen AN; Xu Y; Platanias LC; List AA; Higgins LS; Verma A
Blood; 2006 Dec; 108(13):4170-7. PubMed ID: 16940419
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
3. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
[TBL] [Abstract][Full Text] [Related]
4. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.
Zhou L; Opalinska J; Verma A
Cell Cycle; 2007 Mar; 6(5):534-7. PubMed ID: 17351344
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Zhou L; Nguyen AN; Sohal D; Ying Ma J; Pahanish P; Gundabolu K; Hayman J; Chubak A; Mo Y; Bhagat TD; Das B; Kapoun AM; Navas TA; Parmar S; Kambhampati S; Pellagatti A; Braunchweig I; Zhang Y; Wickrema A; Medicherla S; Boultwood J; Platanias LC; Higgins LS; List AF; Bitzer M; Verma A
Blood; 2008 Oct; 112(8):3434-43. PubMed ID: 18474728
[TBL] [Abstract][Full Text] [Related]
6. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
7. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes.
Shahjahan M; Dunphy CH; Ewton A; Zu Y; Monzon FA; Rice L; Chang CC
Am J Clin Pathol; 2008 Oct; 130(4):635-41. PubMed ID: 18794058
[TBL] [Abstract][Full Text] [Related]
8. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.
Kotsianidis I; Bazdiara I; Anastasiades A; Spanoudakis E; Pantelidou D; Margaritis D; Bourikas G; De Coster R; De Porre P; Tsatalas C
Acta Haematol; 2008; 120(1):51-6. PubMed ID: 18824842
[TBL] [Abstract][Full Text] [Related]
10. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
11. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L; Morrone K; Winski SL; Mantzaris I; Bartenstein M; Ramachandra N; Giricz O; Sukrithan V; Nwankwo G; Shahnaz S; Bhagat T; Bhattacharyya S; Assal A; Shastri A; Gordon-Mitchell S; Pellagatti A; Boultwood J; Schinke C; Yu Y; Guha C; Rizzi J; Garrus J; Brown S; Wollenberg L; Hogeland G; Wright D; Munson M; Rodriguez M; Gross S; Chantry D; Zou Y; Platanias L; Burgess LE; Pradhan K; Steidl U; Verma A
Cancer Res; 2016 Aug; 76(16):4841-4849. PubMed ID: 27287719
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
13. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome.
Braun T; Carvalho G; Coquelle A; Vozenin MC; Lepelley P; Hirsch F; Kiladjian JJ; Ribrag V; Fenaux P; Kroemer G
Blood; 2006 Feb; 107(3):1156-65. PubMed ID: 16223780
[TBL] [Abstract][Full Text] [Related]
14. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
15. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.
Mundle SD; Mativi BY; Bagai K; Feldman G; Cheema P; Gautam U; Reza S; Cartlidge JD; Venugopal P; Shetty V; Gregory SA; Robin E; Rifkin S; Shah R; Raza A
Int J Hematol; 1999 Aug; 70(2):83-90. PubMed ID: 10497846
[TBL] [Abstract][Full Text] [Related]
17. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor.
Mayani H; Baines P; Bowen DT; Jacobs A
Leukemia; 1989 Jan; 3(1):29-32. PubMed ID: 2642575
[TBL] [Abstract][Full Text] [Related]
18. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
19. Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state.
Michalopoulou S; Micheva I; Kouraklis-Symeonidis A; Kakagianni T; Symeonidis A; Zoumbos NC
Leuk Res; 2004 Aug; 28(8):805-12. PubMed ID: 15203278
[TBL] [Abstract][Full Text] [Related]
20. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
